N-&-N, a new class of cell death-inducing kinase inhibitors derived from the purine roscovitine

Molecular Cancer Therapeutics

Volumn 7, Issue 9, 2008, Pages 2713-2724

  Bettayeb, Karima ^a   Sallam, Hatem ^b   Ferandin, Yoan ^a   Popowycz, Florence ^c   Fournet, Guy ^c   Hassan, Moustapha ^b   Echalier, Aude ^d   Bernard, Philippe ^e   Endicott, Jane ^d   Joseph, Benoît ^c   Meijer, Laurent ^a,f  

^a CNRS   (France)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITÉ LYON 1   (France)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e GreenPharma SA   (France)

^f STATION BIOLOGIQUE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; CYCLIN A; CYCLIN DEPENDENT KINASE 2; CYTOCHROME C; GP 0210; GP 0212; MITOGEN ACTIVATED PROTEIN KINASE 1; N AND N1; N AND N2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN MCL 1; PROTEIN P21; PROTEIN P53; PYRIDOXAL KINASE; RETINOBLASTOMA PROTEIN; RNA POLYMERASE II; ROSCOVITINE; SERINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CELL DEATH; CONTROLLED STUDY; CRYSTAL STRUCTURE; DOWN REGULATION; DRUG BINDING; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; DRUG SELECTIVITY; EMBRYO; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME RELEASE; FEMALE; HUMAN; HUMAN CELL; MAXIMUM PLASMA CONCENTRATION; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; RAT; STEADY STATE;

ANIMALS; ANTINEOPLASTIC AGENTS; BICYCLO COMPOUNDS, HETEROCYCLIC; CELL DEATH; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; CYCLIN A; CYCLIN-DEPENDENT KINASE 2; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MODELS, BIOLOGICAL; MODELS, MOLECULAR; NEOPLASM PROTEINS; PROTEIN KINASE INHIBITORS; PURINES; SWINE; TISSUE EXTRACTS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 54049089030     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0080     Document Type: Article

References (49)

1. 2 for control of mitosis in fission yeast. Nature 1981;292:558-60.
2. Lee MG, Nurse P. Complementation used to clone a human homologue of the fission yeast cell cycle control gene cdc2. Nature 1987;237:31-5.
3. Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem Sci 2005;30:630-41.
4. Smith PJ, Yue E, editors. CDK inhibitors of cyclin-dependent kinases as anti-tumor agents. Monographs on enzyme inhibitors. Vol 2. Boca Raton (FL): CRC Press; 2006. p. 448.
5. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006;24:1770-83.
6. Bukanov NO, Smith LA, Klinger KW, Ledbetter SR, Ibraghimov-Beskrovnaya O. Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor Roscovitine. Nature 2006;444:949-52.
7. Rossi AG, Sawatzky DA, Walker A, et al. Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. Nat Med 2006;12:1056-64.
8. Knockaert M, Greengard P, Meijer L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci 2002;123:417-25.
9. Fischer PM, Gianella-Borradori A. Recent progress in the discovery and development of cyclin-dependent kinase inhibitors. Expert Opin Investig Drugs 2005;14:457-77.
10. Misra RN. Clinical progress of selective cyclin-dependent kinase (CDK) inhibitors. Drugs Future 2006;31:43-52.
11. Meijer L, Raymond E. Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc Chem Res 2003;36:417-25.
12. Meijer L, Bettayeb K, Galons H. Roscovitine (CYC202, Seliciclib). In: Yue E, Smith PJ, editors. Monographs on enzyme inhibitors. Volume 2. CDK inhibitors and their potential as anti-tumor agents. CRC Press; 2006. Chap. 9. p. 187-226.
13. Chu XJ, DePinto W, Bartkovitz D, et al. Discovery of [4-amino-2-(1- methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6-methoxyphenyl) methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity. J Med Chem 2006;49:6549-60.
14. DePinto W, Chu XJ, Yin X, et al. In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials. Mol Cancer Ther 2006;5:2644-58.
15. Misra RN, Xiao HY, Kim KS, et al. N-(cycloalkylamino)acyl-2- aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-5-(1,1- dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. J Med Chem 2004;47:1719-28.
16. 1 arrest inprimary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res 2006;66:7661-7.
17. Toogood PL, Harvey PJ, Repine JT, et al. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J Med Chem 2005;48:2388-40.
18. Camidge DR, Pemberton M, Growcott J, et al. A phase I pharmacodynamic study of the effects of the cyclin-dependent kinase-inhibitor AZD5438 on cell cycle markers within the buccal mucosa, plucked scalp hairs and peripheral blood mononucleocytes of healthy male volunteers. Cancer Chemother Pharmacol 2007;60:479-88.
19. Camidge DR, Smethurst D, Growcott J, et al. A first-in-man phase I tolerability and pharmacokinetic study of the cyclin-dependent kinase-inhibitor AZD5438 in healthy male volunteers. Cancer Chemother Pharmacol 2007;60:391-8.
20. Siemeister G, Luecking U, Wagner C, Detjen K, Mc Coy C, Bosslet K. Molecular and pharmacodynamic characteristics of the novel multitarget tumor growth inhibitor ZK 304709. Biomed Pharmacother 2006;60:269-72.
21. Malumbres M, Pevarello P, Barbacid M, Bischoff JR. CDK inhibitors in cancer therapy: what is next? Trends Pharmacol Sci 2008;29:16-21.
22. Meijer L, Borgne A, Mulner O, et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 1997;243:527-36.
23. Bain J, McLauchlan H, Elliott M, Cohen P. The specificities of protein kinase inhibitors: an update. Biochem J 2003;371:199-204.
24. Bain J, Plater L, Elliott M, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J 2007;408:297-315.
25. Bach S, Knockaert M, Reinhardt J, et al. Roscovitine targets, protein kinases and pyridoxal kinase. J Biol Chem 2005;280:31208-19.
26. Tang L, Li MH, Cao P, et al. Crystal structure of pyridoxal kinase in complex with roscovitine and derivatives. J Biol Chem 2005;280:31220-9.
27. Fabian MA, Biggs WH, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005;23:329-36.
28. Becker F, Murthi K, Smith C, et al. A three-hybrid approach to scanning the proteome for targets of small molecule kinase inhibitors. Chem Biol 2004;11:211-23.
29. Vita M, Abdel-Rehim, M, Olofsson, S, et al. Tissue distribution, pharmacokinetics and identification of roscovitine metabolites in rat. Eur J Pharm Sci 2005;25:91-103.
30. Vita M, Meurling L, Pettersson T, Cruz-Siden M, Siden A, Hassan M. Analysis of roscovitine using novel high performance liquid chromatography and UV-detection method: pharmacokinetics of roscovitine in rat. J Pharm Biomed Anal 2004;34:425-31.
31. Nutley BP, Raynaud FI, Wilson SC, et al. Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-roscovitine in the mouse. Mol Cancer Ther 2005;4:125-39.
32. Raynaud FI, Fischer PM, Nutley BP, Goddard PM, Lane DP, Workman P. Cassette dosing pharmacokinetics of a library of 2,6,9-trisubstituted purine cyclin-dependent kinase 2 inhibitors prepared by parallel synthesis. Mol Cancer Ther 2004;3:353-62.
33. Raynaud FI, Whittaker SR, Fischer PM, et al. In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202. Clin Cancer Res 2005;11:4875-87.
34. Gherardi D, D'Agati V, Chu THT, et al. Reversal of collapsing glomerulopathy in mice with the cyclin-dependent kinase inhibitor CYC202. J Am Soc Nephrol 2004;15:1212-22.
35. de la Motte S, Gianella-Borradori A. Pharmacokinetic model of R-roscovitine and its metabolite in healthy male subjects. Int J Clin Pharmacol Ther 2004;42:232-9.
36. Benson C, White J, De Bono J, et al. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-roscovitine) , administered twice daily for 7 days every 21 days. Br J Cancer 2007;96:29-37.
37. McClue SJ, Stuart I. Metabolism of the trisubstituted purine cyclin-dependent kinase inhibitor Seliciclib (R-roscovitine) in vitro and in vivo. Drug Metab Dispos 2008;36:561-70.
38. Guzi T. Cyc-202 Cyclacel. Curr Opin Investig Drugs 2004;5:1311-8.
39. Brown NR, Noble ME, Endicott JA, Johnson LN. The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases. Nat Cell Biol 1999;1:438-43.
40. Bettayeb K, Oumata N, Echalier A, et al. CR8, a potent and selective, roscoritine-derived inhibitor of cyclin-dependent kinases. Oncogene 2008, in press.
41. Collaborative Computational Project, number 4. The CCP4 suite: programs for protein crystallography. Acta Cryst 1994;D50:760-3.
42. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Cryst 2004;D60:2126-32.
43. Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by the maximum-likelihood method. Acta Cryst 1997;D53:240-55.
44. Bettayeb K, Tirado OM, Marionneau-Lambert S, et al. Meriolins, a new class of cell death inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases. Cancer Res 2007;67:8325-34.
45. Reinhardt J, Ferandin Y, Meijer L. Purification CK1 by affinity chromatography onimmobilised axin. Protein Expr Purif 2007;54:101-9.
46. Ribas J, Boix J. Cell differentiation, caspase inhibition, and macromolecular synthesis blockage, but not BCL-2 or BCL-XL proteins, protect SH-SY5Y cells from apoptosis triggered by two CDK inhibitory drugs. Exp Cell Res 2004;295:9-24.
47. Ribas J, Boix J, Meijer L. (R)-roscovitine (CYC202, Seliciclib) sensitizes SH-SY5Y neuroblastoma cells to nutlin-3-induced apoptosis. Exp Cell Res 2006;312:2394-400.
48. Shah VP, Midha KK, Dighe S, et al. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Eur J Drug Metab Pharmacocinet 1991;16:249-55.
49. Shah VP, Midha KK, Findlay JW, et al. Bioanalytical method validation - a revisit with a decade of progress. Pharm Res 2000;17:1551-7.